Qelbree (viloxazine) is not a controlled substance. It has no DEA schedule classification, which sets it apart from stimulant ADHD medications like Adderall and Ritalin that are classified as Schedule II controlled substances. This distinction affects how the medication is prescribed, refilled, and perceived in terms of abuse risk.
Why Qelbree Is Not Controlled
The DEA assigns controlled substance schedules based on a drug’s potential for abuse and physical dependence. Stimulant ADHD medications fall under Schedule II because they act on dopamine pathways in ways that can produce euphoria at high doses. Qelbree works differently. Rather than directly flooding the brain with dopamine the way stimulants do, it primarily modulates serotonin activity in the prefrontal cortex while also moderately blocking the reuptake of norepinephrine. This pharmacological profile doesn’t produce the rewarding “high” associated with stimulant misuse, which is why the FDA did not recommend a controlled substance designation.
In clinical trials involving over 2,000 pediatric patients and hundreds of adults, the side effect profile showed no signals typical of drugs with abuse potential, such as euphoria or drug-seeking behavior. The most common side effects in adults were insomnia (13.8%), nausea (13.8%), headache (10.7%), and fatigue (10.1%). In children and adolescents, sleepiness was particularly common, affecting about 17% of patients in trials.
What This Means for Prescriptions and Refills
Because Qelbree is not a controlled substance, the prescription process is simpler than it is for stimulants. Stimulant ADHD medications come with tight restrictions: many states limit you to a 30-day supply at a time, prohibit automatic refills, and require a new prescription for each fill. Some states also mandate regular in-person visits before a provider can continue prescribing.
With a non-controlled medication like Qelbree, your provider can typically write a prescription with refills, and you won’t face the same quantity limits or scheduling hurdles. This can be a practical advantage if you have difficulty getting to frequent appointments or if pharmacy shortages (which have been a recurring problem with stimulant medications) create gaps in your treatment. Qelbree still requires a prescription, but the regulatory burden is lighter on both you and your prescriber.
How Qelbree Compares to Stimulants
Qelbree belongs to the non-stimulant category of ADHD treatments, alongside medications like atomoxetine and guanfacine. Non-stimulants generally take longer to reach full effect and may be less potent for some people than stimulants, but they carry a lower risk of misuse and dependence. For people with a history of substance use disorders, or for parents who prefer a non-controlled option for their child, this can be a deciding factor.
That said, “non-controlled” does not mean “without serious risks.” Qelbree carries a boxed warning, the FDA’s most prominent safety alert, regarding suicidal thoughts and behaviors. In pediatric trials, 0.9% of children and adolescents taking Qelbree reported suicidal ideation or behavior, compared to 0.4% on placebo. Among adults, 1.6% of those on Qelbree reported suicidal ideation versus none on placebo. These rates are low in absolute terms, but they warrant close monitoring, especially during the first few months or when doses change.
Drug Interactions to Know About
Qelbree is a strong inhibitor of a liver enzyme called CYP1A2, which your body uses to break down a range of common substances. Caffeine is one of the most notable: Qelbree can increase caffeine exposure by four to nearly six times, meaning your usual cup of coffee could hit significantly harder. If you notice unusual jitteriness, insomnia, or a racing heart after starting Qelbree, your caffeine intake is a likely culprit.
Other medications metabolized by the same enzyme can also build up to problematic levels. In one documented case, the asthma drug theophylline doubled in blood concentration within three days of starting viloxazine, causing signs of toxicity. The anti-seizure medication carbamazepine showed a similar interaction. Qelbree also weakly inhibits two other liver enzymes, which can modestly increase levels of certain other drugs. If you take multiple medications, your provider will need to review potential interactions before adding Qelbree.
Dosing Across Age Groups
Qelbree is approved for children ages 6 and older, adolescents, and adults. The starting dose and maximum dose differ by age group. Children ages 6 to 11 typically start at 100 mg once daily, with the option to increase by 100 mg each week up to a maximum of 400 mg. Adolescents ages 12 to 17 start at 200 mg, with a possible increase to 400 mg after one week. Adults also start at 200 mg but can go up to 600 mg per day, titrating in 200 mg increments on a weekly basis. The capsules are taken once daily, which simplifies the routine compared to some stimulants that require multiple doses throughout the day.
Because Qelbree is not a controlled substance, the process of adjusting your dose with your provider tends to be more straightforward. There’s no need for a new prescription each time the dose changes, and pharmacies don’t face the same regulatory scrutiny when dispensing it.